These findings indicate that genes directly or indirectly regulated by ANXA2 retain a consistent prognostic relevance and that ANXA2 is endowed with the ability to participate in multiple cancer processes, fundamental for tumor survival, thus being a potential therapeutic target in GBM. This evidence concerns the gene ANXA2 and glioblastoma.